ClinicalTrials.gg
CompletedNCT04991571Updated Nov 23, 2021

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

A Phase 1 interventional study of Zibotentan (Treatment A) and Dapagliflozin (Treatment A) in Chronic Kidney Disease, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-23.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic — 15 open to participants now, 21 under way, 7 of them phase 3. dapagliflozin · Renal Insufficiency, Chronic.

Enrollment
35th of 40
27 · median 100
Started
2021
with 4 others
Phase 1
2 of 40
none open now
Registered
7th of 40
by date
Lead sponsor
9 of 40
AstraZeneca

Among the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, this one is the 35th largest by enrollment, is one of 5 that started in 2021, is one of 2 in phase 1, and was the 7th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

15 of the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The study will have 2 independent parts:

Part 1 of the study is intended to collect samples for Metabolites in Safety Testing (MIST) analysis after administration of multiple doses of zibotentan.

Part 2 of the study is designed to evaluate the relative bioavailability of zibotentan and dapagliflozin after dosing with two different fixed-dose combination (FDC) formulations and dosing with separate formulations of zibotentan and dapagliflozin.

Read the detailed description

Part 1 will be an open-label, non-randomised, single treatment period. A single treatment period during which participants will be resident at the study centre from 2 days before dosing (Day -2) until the morning of Day 6.

Part 2 will be an open-label, randomised, 3-period, 3-treatment, cross-over single dose study. Participants will be randomised to one of 3 treatment sequences and will receive 3 single-dose study interventions. Participants will be resident at the study centre from 2 days before dosing (Day -2) until Day 3 of the last treatment sequence.

Participants who were enrolled in Part 1 may not be enrolled in Part 2.

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the study participants should fulfil the following criteria:

  1. Participants with suitable veins for cannulation or repeated venipuncture.
  2. Females must have a negative pregnancy test at the Screening Visit and within 24 hours prior to dosing, must not be lactating and must be of non-
  3. Male participant must adhere to the methods.
  4. Have a between 18 and 29.9 kg/m\^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
  5. Provision of signed and dated, written prior to any study specific procedures.

Exclusion criteria

Exclusion Criteria:

Participants will not enter the study if any of the following exclusion criteria are fulfilled:

  1. History or presence of gastrointestinal, hepatic or renal disease or any important disease or disorder.
  2. Any illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention.
  3. Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis.
  4. Any positive result on screening for serum surface antigen, antibody, and antibody.
  5. Abnormal vital signs. 6 History of drug abuse or alcohol abuse.
  1. History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  1. Participants who are vegans or have medical dietary restrictions. 9. Participants tested positive for COVID-19 at the time of randomisation or have been previously hospitalised with COVID-19 infection.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Part 1

    Participants will be administered with zibotentan once daily for 5 days.

    Drug: Zibotentan (Treatment A)

  • Experimental
    Part 2: Treatment Sequence ABC

    Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment A; Treatment B; Treatment C) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.

    Drug: Zibotentan (Treatment A) · Drug: Dapagliflozin (Treatment A) · Drug: Zibotentan/Dapagliflozin - Formulation 1 (Treatment B) · Drug: Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)

  • Experimental
    Part 2: Treatment Sequence BCA

    Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment B; Treatment C; Treatment A) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.

    Drug: Zibotentan (Treatment A) · Drug: Dapagliflozin (Treatment A) · Drug: Zibotentan/Dapagliflozin - Formulation 1 (Treatment B) · Drug: Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)

  • Experimental
    Part 2: Treatment Sequence CAB

    Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment C; Treatment A; Treatment B) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.

    Drug: Zibotentan (Treatment A) · Drug: Dapagliflozin (Treatment A) · Drug: Zibotentan/Dapagliflozin - Formulation 1 (Treatment B) · Drug: Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)

Interventions

  • Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.

  • Dapagliflozin tablet will be administered orally as single dose in Part 2.

  • DrugZibotentan/Dapagliflozin - Formulation 1 (Treatment B)

    Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.

  • DrugZibotentan/Dapagliflozin - Formulation 2 (Treatment C)

    Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.

06

What researchers measure

Primary outcomes

  1. Part 1: Metabolites in Safety Testing sampling

    Plasma sample will be collected to understand the PK profiling of zibotentan metabolites and to meet the regulatory requirements.

    Time frame: Day 1 through Day 6 (pre-dose, 30 min; 1, 2, 4, 6, 8, 12 and 24 hours post dose)

  2. Part 2: Area under plasma concentration time curve from zero to infinity (AUCinf)

    Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated.

    Time frame: Day 1 through Day 3 of each treatment period

  3. Part 2: Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)

    Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated.

    Time frame: Day 1 through Day 3 of each treatment period

  4. Part 2: Maximum observed plasma drug concentration (Cmax)

    Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated.

    Time frame: Day 1 through Day 3 of each treatment period

  5. Part 2: Observed concentration at 24 hours post-dose (C24)

    Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated.

    Time frame: Day 1 through Day 3 of each treatment period

Secondary outcomes

  1. Part 2: Time to reach peak or maximum observed concentration (tmax)

    Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated.

    Time frame: Day 1 through Day 3 of each treatment period

  2. Part 2: Terminal rate constant (λz)

    Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated.

    Time frame: Day 1 through Day 3 of each treatment period

  3. Part 2: Half life associated with λz (t½λz)

    Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated.

    Time frame: Day 1 through Day 3 of each treatment period

  4. Part 2: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated.

    Time frame: Day 1 through Day 3 of each treatment period

  5. Part 2: Volume of distribution at steady state following extravascular administration (Vz/F)

    Relative bioavailability of zibotentan and dapagliflozin after dosing with two different FDC formulations and dosing with separate formulations of zibotentan and dapagliflozin will be evaluated.

    Time frame: Day 1 through Day 3 of each treatment period

  6. Part 1 and Part 2: Number of adverse events and serious adverse events

    Safety and tolerability of zibotentan and dapagliflozin will be studied.

    Time frame: From Sceerning to Follow-up Visit approximately 40 days for Part 1 and 49 days for Part 2

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Oct 2021, 2 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2021
First posted
Aug 5, 2021
StartActual
Jul 29, 2021
Primary completionActual
Oct 22, 2021
CompletionActual
Oct 22, 2021
Last update
Nov 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04991571
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 5, 2021
Start date
Jul 29, 2021
Primary completion
Oct 22, 2021
Completion
Oct 22, 2021
Last update
Nov 23, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ZD4054 · Dapagliflozin

Start the discussion